Synchronoss Welcomes Mary Clark as Chief Marketing Officer and Executive Vice President
Synchronoss Technologies, Inc. (NASDAQ:SNCR) (the “Company” or “Synchronoss”), a global leader and innovator in cloud, messaging and digital products, has appointed Mary Clark as its new Chief Marketing Officer and Executive Vice President of Product. Ms. Clark offers more than 25 years of mobile industry experience. She is a highly visible and well-respected industry thought leader, regularly speaking at major global industry events, on a wide range of issues. In her new role at Synchronoss, Ms. Clark will be responsible for product management, marketing and communications.
Prior to joining Synchronoss, Ms. Clark served as Chief Corporate Relations Officer and Chief of Staff at Syniverse. Previously, she acted as Chief Marketing Officer and Senior Vice President of Roaming. During her tenure, she was a key player across many areas of the business: from running global financial settlements and delivering the first real-time intelligence solutions to the roaming market, to leading a successful acquisition and merger with MACH of Luxemburg. Additionally, in 2017 Ms. Clark was awarded a Silver Anvil Award from the Public Relations Society of America for a campaign that put Syniverse in the center of the discussion for mobile engagement for brands and enterprises.
“I’ve had the pleasure of knowing Mary for more than seven years, and have seen firsthand the impact, respect and influence she has built in the industry. I can personally attest to not only her talent, but also her warm and engaging character,” said Glenn Lurie, Chief Executive Officer and President of Synchronoss. “Mary will be an exceptional addition, and a phenomenal fit within our existing executive team. She is a world-class leader and we are thrilled to welcome her and know she will be a strategic driver of our future success.”
Ms. Clark has served as a Board member for the Competitive Carriers Association, and the CTIA Wireless Foundation, and currently serves on the CMO Advisory Council. She has been a contributing writer for Global Telecoms Business and CMO.com and has several honors to her name, including being named to the National Diversity Council’s “Top 50 Most Powerful Women in Technology” list in 2016 and 2017. Ms. Clark earned her Bachelor of Arts in communications from the University of Delaware.
“Synchronoss is uniquely positioned to capitalize on a wealth of new opportunity in the Telecom, Media and Technology industries,” said Mary Clark, Chief Marketing Officer, Synchronoss. “Its market-leading offers in cloud, messaging and digital transformation have the power to disrupt and revolutionize how carriers and technology companies engage, monetize, and retain their customers. Synchronoss has a long and proud history in achieving real differentiation through high quality customer experience. I am proud to work with Glenn and his executive team to keep Synchronoss at the forefront as the partner technology companies need to drive growth in this dynamic ecosystem.”
Synchronoss (NASDAQ: SNCR) transforms the way companies create new revenue, reduce costs and delight their subscribers with cloud, messaging and digital products supporting hundreds of millions of subscribers across the globe. Synchronoss’ secure, scalable and groundbreaking new technologies, trusted partnerships and talented people change the way TMT customers grow their business. For more information, visit us at www.synchronoss.com
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F24.4.2018 20:30 | Pressemelding
Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC). These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov). Printed copies of these documents are also
Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 16:00 | Pressemelding
Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 15:53 | Pressemelding
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm
Temasys Communications and Appian Partner to Power Real-Time Communications in the Contact Center24.4.2018 15:00 | Pressemelding
Temasys Communications announced today that Appian has integrated with the Temasys Skylink technology, enabling real-time communications, including chat and co-browsing, in Appian’s new Intelligent Contact Center (ICC) Platform. “For our contact center customers, omni-channel communications are essential. Appian is working with Temasys to provide contact centers with real-time communication channels such as chat and co-browsing via the Temasys versatile SDKs,” said Arturo Oliver, Senior Director of Product Strategy at Appian. Temasys Skylink APIs will be compatible with the Appian Intelligent Contact Center Platform, making it easy for Appian customers to add real-time communication to their applications, including chat, voice, video and co-browsing. These integrations enable users to visit a website, begin a chat session that seamlessly escalates to a voice call and extend to co-browsing — all without changing apps or establishing a new connection. “We’re thrilled to work with Appian
PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 13:07 | Pressemelding
PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b
Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 12:17 | Pressemelding
Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr